XOMA vs BCYC vs PRAX vs RCUS

For growth investors, Bicycle Therapeutics plc (BCYC) is the stronger pick with 105.

8% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). XOMA Royalty Corp. (XOMA) offers the better valuation at 28. 3x trailing P/E (36. 7x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, XOMA Royalty Corp.

(XOMA) delivered a total return of +30. 0%, compared to -84. 6% for Bicycle Therapeutics plc (BCYC). Over 10 years, the gap is even starker: XOMA returned +186. 7% versus BCYC's -59. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), XOMA Royalty Corp.

(XOMA) is the lower-risk stock at 1. 21β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 61% more volatile than XOMA relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bicycle Therapeutics plc (BCYC) is pulling ahead at 105.

8% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -301. 7% for Bicycle Therapeutics plc — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMA leads at 21. 8% versus -341. 3% for BCYC. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BCYC: 118.

2% to $10. 67.

In this comparison, XOMA (0.

7% yield) pays a dividend. BCYC, PRAX, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XOMA Royalty Corp.

(XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), 0. 7% yield, +186. 7% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XOMA: +186. 7%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XOMA is a small-cap high-growth stock; BCYC is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock. XOMA pays a dividend while BCYC, PRAX, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.